I am part of the implementation group at the Institute of Chemical Processes at the Czech Academy of Sciences, which cooperates with several other institutes of the Czech Academy of Sciences and research groups at several universities on a project focusing on regenerative medicine.

“Regenerative medicine is a new prospective field focused on repairing or replacing tissues or organs that have lost their function due to old age, disease, damage or congenital defects. It is a multidisciplinary field including tissue engineering, molecular biology and nanotechnology. The research agenda of the project includes the creation and development of an excellent research Center focused on R&D in the field of regenerative medicine therapeutic methods, which have the potential in the longer term to create applicable results of research and development, and which will contribute to the development of the competitiveness of the Czech Republic in the given field. The excellence and uniqueness of the project lies in the fact that its research intentions aim at restoring tissues whose damage is not yet curable, or their regenerative capacity is greatly limited. These include mainly damage to the nerve tissue of the brain and spinal cord, including the problem of neurodegeneration and retinal degeneration, as well as the replacement of small-diameter blood vessels, which are still missing on the market (or in clinical practice), and last but not least the active healing of chronic wounds and osteochondral defects, which also belong to the serious problems of modern civilized society. The unifying element of the whole project are the “Medical devices for modern therapies", namely products for gene therapy, somatic cell therapy and tissue engineering products." - that's the annotation to this project from our cooperating BUT

As part of this project in the laboratory of Bioorganic Chemistry and Biomaterials, we prepare and characterise a completely novel platform of multivariable dendrimers (branched polymer molecules) based on easily functionalizable carbosilanes, which will be used as carriers for planned regenerative applications in the next phases of the project. In our case, it is primarily an application in the treatment of osteochondral defects. Our carriers should transport (not only) growth factors more easily and efficiently to target sites of these defects supporting there the repair of damaged or missing tissue.

Development of treatment of osteochondral defects
Projekt: Excellence Research in Regenerative Medicine (ExRegMed, OP JAK)
Principal Investigator at ICPF CAS: Ing. Tomáš Strašák, Ph.D.
Duration of the project: 10/2023–06/2028